LE Minerals【LEL】銘柄情報

LE Minerals Ltd (LEL) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.32

( -1.54% )

買値

0.315

売値

0.32

出来高

907,182

0.31 日の範囲 0.33

0.295 52 週間の範囲 0.45

時価総額

35.841M

前日終値

0.325

始値

0.325

時刻

34974

0.32

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

AUD 184,671

発行済株式数

112,001,569

配当利回り

PER

-7.96

1 株当たり利益 (EPS)

0.46

歳入

純利益

51.96M

LE Minerals Limited, a battery minerals company, engages in the exploration, evaluation, and development of lithium and graphite mineral properties in Australia and Argentina. Its flagship projects are the Solaroz Lithium Brine project that consists of 8 mineral concessions covering an area of appro... LE Minerals Limited, a battery minerals company, engages in the exploration, evaluation, and development of lithium and graphite mineral properties in Australia and Argentina. Its flagship projects are the Solaroz Lithium Brine project that consists of 8 mineral concessions covering an area of approximately 12,000 hectares located in Argentina; and the Burke Graphite project located in the Cloncurry region in North Central Queensland, Australia. The company was formerly known as Lithium Energy Limited and changed its name to LE Minerals Limited in May 2026. LE Minerals Limited was incorporated in 2021 and is headquartered in West Perth, Australia. 詳細を表示

セクター

Materials

業界

Mining

ウェブサイト

lithiumenergy.com.au

本社

Perth, Australia

設立

2026

LE Minerals Ltd is listed in the Materials sector of the オーストラリア証券取引所 with ticker LEL. The last closing price for LE Minerals was AUD0.33. Over the last year, LE Minerals shares have traded in a share price range of AUD 0.295 to AUD 0.45.

LE Minerals currently has 112,001,569 shares in issue. The market capitalisation of LE Minerals is AUD35.84 million. LE Minerals has a price to earnings ratio (PE ratio) of -7.96.

Lilly Expresses Concerns With Opinion of ADA

Date: For Release: Immediately Refer to: (317) 433-8990 Marni Lemons (317) 276-3570 Jeff Newton Lilly Expresses Concerns With Opinion of ADA...

Lilly Participates in Medicare Prescrip. Drug Card

Date: January 21 , 2004 For Release: Immediately Refer to: 317-433-9899 - Edward Sagebiel 317-277-1302 - Rob Smith Lilly Unveils Participation...

FDA Approves Zyprexa for Bipolar Disorder

Date: January 15, 2004 For Release: Immediately Refer to: Marni Lemons 317-433-8990 FDA Approves Zyprexa?for Maintenance of Bipolar Disorder...

Lilly Launches Third Venture Capital Fund

Date: January 12, 2004 For Release: Immediately Refer to: (317) 433-5058 - Karin Ricketts Lilly Launches Third Venture Capital Fund Lilly MedTech...

Date/Time -Lilly's fourth-quarter 2003 results

Date: January 7, 2004 For Release: Immediately Refer to: (317) 276-5795 - Terra L. Fox Lilly Sets Date and Conference Call for Fourth-Quarter and...

Lilly Announces 2004 Financial Guidance

Lilly Announces 2004 Financial Guidance INDIANAPOLIS, Jan. 5 -- Eli Lilly and Company (NYSE: LLY) today announced its financial expectations for...

Lilly Announces FDA Approval of First Medication for Bipolar Depression; Symbyax Combines Active Ingredients of Zyprexa and Proz

Eli Lilly and Company Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Symbyax(TM...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.025	-7.24637681159	0.345	0.345	0.31	91527	0.33370047	DE
4	-0.05	-13.5135135135	0.37	0.425	0.31	134089	0.37439119	DE
12	-0.05	-13.5135135135	0.37	0.425	0.295	176379	0.33752256	DE
26	-0.07	-17.9487179487	0.39	0.45	0.295	208786	0.35098846	DE
52	-0.035	-9.85915492958	0.355	0.45	0.295	205845	0.35098846	DE
156	-0.51	-61.4457831325	0.83	0.95	0.27	165541	0.52700164	DE
260	-0.07	-17.9487179487	0.39	1.82	0.27	317179	0.82096091	DE